{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Banglun Pan"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0011626000"],"submitter_email":["1335563838@qq.com"],"submitter_affiliation":["Fujian Medical University"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"name_synonyms":["dfxr1, FMR1, NEOPL LIVER, dmfr1, primary tumour of the liver, resectable malignant neoplasm of the liver, l(1)G0418, dFMRP, Neoplasms, Fzr/rap, Benign Neoplasm, bar, Cdh1, CDH1, adult hepatoma, Cdh1[Fzr], hepatic, Tumor, Hepatic Neoplasm, BcDNA:GM08679, Malignant, hepatocellular carcinoma plus intrahepatic cholangiocarcinoma, rap/fizzy-related, primary liver cancer, fzr, MAGE-E1 antigen, Readability, liver, dFMR1, dFmr1, Cdh[Fzr], HRR-1, dFZR, fmr1, Immune., primary, not specified as primary or secondary, Fmrp, Immune Processes, FMRp, Immune Responses, Hepatic Cancer, Liver Cancer, Malignancy, primary malignant neoplasm of Liver, Cancer of the liver, EP(3)3517, adult primary hepatocellular carcinoma, Liver Cancers, Hepatic Neoplasms, dFXRP, malignant neoplasm of liver, AI847422, hepatic cancer, rap/Fzr, Neoplasias, DmelCG3000, FMRP, malignant hepato-biliary neoplasm, Resectable malignant neoplasm of Liver, Immune Response, Immune, Cdh1/Fzr, primary malignant neoplasm of liver, xfor, FMR, HCA1, wex, dFmrp, l(1)G0326, Hepatic, Malignancies, Rap/Fzr, CG6203, Cancer of the Liver, dFXR1, hepatic neoplasm, RIP14, Immune Process, rap/fzr, Cancer, liver Cancer, Tumors, agonista, Liver, HRR1, dfmr, Malignant Neoplasm, Hepatic Cancers, fmr, Process, rip14, primary tumor of the liver, Alpha-dystrobrevin-associated MAGE Protein, Cancer of Liver, primary cancer of liver, liver Cancers, cg6203, Cell, hrr-1, Benign, dFMR, Rxrip14, agonist, APC/C[Fzr/Cdh1], Liver Neoplasm, DAMAGE, Hepatocellular carcinoma-associated protein 1, Neoplasm, agonists, hrr1, agoniste, DmelCG6203, FXR, Fxr, cdh1, ca liver - primary, AI957360, RGD1560259, non-resectable primary hepatic malignant neoplasm, dfxr, CG3000, Benign Neoplasms, Cancers, Understanding, malignant tumor of liver, dfmr1, Malignant Neoplasms, fxr, neoplasm of liver, anon-WO03040301.193, AT24755, Ca liver - primary, Hepatocellular Cancers, Hepatocellular, LIVER NEOPL, Response, dFXR, Cancer of liver, BAR, other neoplasm, mMage-e1, Hepatocellular Cancer, Neoplasia, redax, Hec/Cdh[Fzr], Fzr, Hepatitis B"],"description_synonyms":["HYCC1, Carcinomas, NK Cell, Natural Killer Cells, Carcinoma, DRCTNNB1A, Liver, NK Cells, Adult Liver Cancers, Hepatocellular carcinoma, Liver Cancer, Natural Killer Cell, Hepatoma, Natural, adult primary hepatocellular carcinoma, Liver Cancers, Cell Carcinoma, HLD5, Liver Cell, Cancers, adult hepatoma, Adult, Hepatomas, Liver Cell Carcinoma, Cell, Hepatocellular Carcinoma, Cell Carcinomas, large granular lymphocyte, Killer Cell, HCC, Liver Cell Carcinomas, Cells, proteomic analysis, Adult Liver Cancer, null cell, Hepatocellular., Adult Liver, NK cell, Hepatocellular Carcinomas, NK, Natural Killer, Hepatitis B, Cancer"],"additional_accession":[]},"is_claimable":false,"name":"New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity","description":"To elucidate the mechanism by which Vonafexor enhanced T and NK cell function, we conducted a proteomic analysis of immune cells derived from HBV-positive HCC following stimulation with Vonafexor.","dates":{"publication":"Tue Apr 08 00:00:00 BST 2025"},"accession":"PXD062758","cross_references":{"TAXONOMY":["9606"]}}